- Home
- PBYI vs CMPX Comparison
PBYI vs CMPX Comparison
Compare PBYI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CMPX
- Stock Information
- Founded
- PBYI 2010
- CMPX 2014
- Country
- PBYI United States
- CMPX United States
- Employees
- PBYI N/A
- CMPX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- CMPX Health Care
- Exchange
- PBYI Nasdaq
- CMPX Nasdaq
- Market Cap
- PBYI 153.2M
- CMPX 214.6M
- IPO Year
- PBYI N/A
- CMPX N/A
- Fundamental
- Price
- PBYI $3.09
- CMPX $2.00
- Analyst Decision
- PBYI Strong Buy
- CMPX Strong Buy
- Analyst Count
- PBYI 1
- CMPX 4
- Target Price
- PBYI $7.00
- CMPX $13.75
- AVG Volume (30 Days)
- PBYI 754.5K
- CMPX 1.8M
- Earning Date
- PBYI 02-27-2025
- CMPX 11-12-2024
- Dividend Yield
- PBYI N/A
- CMPX N/A
- EPS Growth
- PBYI 492.79
- CMPX N/A
- EPS
- PBYI 0.47
- CMPX N/A
- Revenue
- PBYI $243,569,000.00
- CMPX $850,000.00
- Revenue This Year
- PBYI N/A
- CMPX N/A
- Revenue Next Year
- PBYI N/A
- CMPX $613.39
- P/E Ratio
- PBYI $6.63
- CMPX N/A
- Revenue Growth
- PBYI 6.30
- CMPX N/A
- 52 Week Low
- PBYI $2.23
- CMPX $0.77
- 52 Week High
- PBYI $7.73
- CMPX $2.68
- Technical
- Relative Strength Index (RSI)
- PBYI 49.17
- CMPX 65.48
- Support Level
- PBYI $2.92
- CMPX $1.43
- Resistance Level
- PBYI $4.06
- CMPX $2.68
- Average True Range (ATR)
- PBYI 0.29
- CMPX 0.24
- MACD
- PBYI 0.01
- CMPX 0.06
- Stochastic Oscillator
- PBYI 27.07
- CMPX 46.87
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.